Current Oncology Reports

, Volume 14, Issue 6, pp 539–543

Surgery for Relapsed Ovarian Cancer: When Should it Be Offered?

Gynecologic Cancers (NS Reed, Section Editor)

DOI: 10.1007/s11912-012-0260-x

Cite this article as:
Harter, P., Heitz, F. & du Bois, A. Curr Oncol Rep (2012) 14: 539. doi:10.1007/s11912-012-0260-x


Whilst cytoreductive surgery is the mainstay treatment for primary ovarian cancer, its role in relapse is still unclear. Surgery in platinum-sensitive recurrent ovarian cancer might be beneficial if it results in complete resection of the disease. Clinical scores could help to identify suitable patients. Level I evidence is still missing; however, two randomized trials (DESKTOP III and GOG 213) are ongoing.


Ovarian cancer Surgery Recurrent ovarian cancer Secondary cytoreductive surgery AGO score 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Philipp Harter
    • 1
  • Florian Heitz
    • 1
  • Andreas du Bois
    • 1
  1. 1.Department of Gynecology and Gynecologic OncologyKliniken Essen-MitteEssenGermany

Personalised recommendations